We are delighted to announce the winner of the 2020 Statistical excellence in the pharmaceutical industry award, presented jointly by the RSS and Statisticians in the Pharmaceutical Industry (PSI)...
Dr. Sandeep M Menon, Senior Vice President and Head of Early Clinical Development at Pfizer has won the prize for “Influential Quantitative Leadership in several domains in Early Clinical Development - creating a culture of quantitative decision making within a major pharmaceutical company.”
The judging panel found Dr Menon’s work to be an impressive demonstration of the value of biostatistics as well as an effective promotion of statistical thinking within a large organisation.
Tim Rolfe, chair of the PSI award committee said “Dr Menon is a well deserving winner of this year's award. His impact as an innovative statistical leader shone through-out the successful nomination.”
On winning the award, Dr Menon said: “It’s an honour to receive this award in recognition of the use of innovative statistical and digital tools to influence quantitative decision making in early clinical development. These tools not only quantify the probability of success but also help executive leadership make informed decisions to bring breakthrough therapies to patients quickly and safely.”
The award was due to be presented at the annual PSI Conference, but this sadly had to be cancelled this year due to the Covid-19 pandemic.
This course is aimed at clinical trial statisticians who are new to or with limited experience of machine learning. Attendees will learn about a range of topics in machine learning, including practical sessions in R.
This webinar will explore two different approaches to Correlates of Protection in vaccine development.
Our monthly webinar explores examples of innovative data visualisations relevant to our day to day work. Each month a new dataset is provided from a clinical trial or other relevant example, and participants are invited to submit a graphic that communicates interesting and relevant characteristics of the data.
The event will open with an overview on drug development in women’s health from a clinician perspective. This talk is followed by talks about statistical challenges when planning IVF studies and analysing the menstrual cycles.
This webinar will provide an overview of surrogacy for licensing and reimbursement. In turn, the need of extensions of the SPIRIT and CONSORT statement will be defined and outlined, with case studies to support.
Lea Vaas will present how replacement of concurrent control animals by Virtual Control Groups (VCGs) in systemic toxicity studies may help in contributing to the 3R's principle of animal experimentation: Reduce, Refine, Replace.
We will share a brief overview of what Mobilise D is and why it is an important step stone in the development of digital biomarkers, and how Mobilise D outputs can be relevant for you.
This networking event is aimed at statisticians that are new to the pharmaceutical industry who wish to meet colleagues from different companies and backgrounds.
This networking event is aimed at statisticians that are new to the pharmaceutical industry who wish to meet colleagues from different companies and backgrounds.
An introductory course giving an overview of the pharmaceutical industry and the drug development process as a whole, aimed at those with 1-3 years' experience. It comprises of six 2-day sessions covering a range of topics including Research and Development, Toxicology, Data Management and the Role of a CRO, Clinical Trials, Reimbursement, and Marketing.
This networking event is aimed at statisticians that are new to the pharmaceutical industry who wish to meet colleagues from different companies and backgrounds.
We have exciting new opportunities available for Study Statisticians, Support Statisticians and Exploratory Statisticians at various levels.
